CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Onkure Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Onkure Therapeutics Inc
6707 Winchester Circle, Suite 400
Phone: (720) 307-2892p:720 307-2892 BOULDER, CO  80301  United States Ticker: OKUROKUR
Business Summary
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board AndrewPhilips 10/4/2024 10/4/2024
President, Chief Executive Officer, Director Nicholas A.Saccomano 64 10/4/2024 10/4/2024
Chief Financial Officer Jason A.Leverone 10/4/2024 10/4/2024
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
RENEO PHARMA LTD Innovation House Office 13, Second Floor Discovery Park Kent United Kingdom
OnKure, Inc. 6707 Winchester Circle, Suite 400 Boulder CO United States

Business Names
Business Name
OKUR
OnKure, Inc.
Radiate Merger Sub II, LLC
RPHM

General Information
Number of Employees: 46 (As of 3/7/2025)
Outstanding Shares: 13,441,875 (As of 4/1/2025)
Shareholders: 60
Stock Exchange: NASD
Federal Tax Id: 472309515
Fax Number: (302) 674-5266


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025